Last reviewed · How we verify
NCT03597659: PHETHYR
PheWAS of a Polygenic Predictor of Thyroid Function
trial testing phenome-wide association study (PheWAS) in Thyroid in 37,154 participants. Completed in 1 July 2018.
1 July 2018
Quick facts
| Lead sponsor | Groupe Hospitalier Pitie-Salpetriere |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 37,154 |
| Start date | 1 September 2017 |
| Primary completion | 1 July 2018 |
| Estimated completion | 1 July 2018 |
| Sites | 1 location across France |
Drugs / interventions tested
- phenome-wide association study (PheWAS)
Conditions studied
- Thyroid — all drugs for Thyroid →
- Genetic Predisposition to Disease — all drugs for Genetic Predisposition to Disease →
Sponsor
Groupe Hospitalier Pitie-Salpetriere
Who can join
Adults 28 to 100, any sex, with Thyroid or Genetic Predisposition to Disease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Performing a phenome-wide association study (PheWAS) identifying clinical diagnoses associated with a polygenic predictor of Thyroid stimulating hormone (TSH) levels identified by a previously published genome-wide association study (GWAS). PheWAS will be applied in an electronic-health-record (EHR) cohort including North American (n: 37,154) and European participants using 1,318 phenotypes.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03597659
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Thyroid
Currently open trials in the same condition.
- NCT07296575 — Ultrasound Large-scale Model in Thyroid Field: A Multi-center Study on Medical-Engineering Integration · active not recruiting
- NCT06800482 — A Study of Online Follow-up in Patients With Papillary Thyroid Cancer · NA · recruiting
- NCT04845867 — A Prospective, Single-arm, Multi-centre, Blinded, Observational, Diagnostic Accuracy Study With a Diagnostic Medical Pro · recruiting
- NCT06419556 — Analgesic Efficacy of an Intermediate CPB in Neck Surgeries. · NA · recruiting
- NCT05733013 — A Study to Collect Information About the Use of Redifferentiating Medications as a Standard Treatment for Thyroid Cancer · recruiting
Other Groupe Hospitalier Pitie-Salpetriere trials
Trials by the same sponsor.
- NCT06515678 — Impact of Antihypertensive Therapy on Recurrence Risk of Ovarian Cancer for Bevacizumab-associated Hypertension · active not recruiting
- NCT05934214 — EXploring Immune-related Adverse Events of Immune checkpoinT Inhibitors Using VigiBase, the WHO Pharmacovigilance Databa · completed
- NCT05819736 — Pharmacokinetics Study Of Rivaroxaban and Apixaban in Cancer Patients · unknown
- NCT04320017 — Joint Use of Electrocardiogram and Transthoracic Echocardiography With Other Clinico-biological Parameters in an Observa · completed
- NCT04314817 — Adverse Events Related to Treatments Used Against Coronavirus Disease 2019 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03597659 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Groupe Hospitalier Pitie-Salpetriere
- Last refreshed: 26 September 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03597659.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing